Abstract
Although the pathophysiological mechanisms underlying the development of amyotrophic lateral sclerosis (ALS) remain to be fully elucidated, there have been significant advances in the understanding of ALS pathogenesis, with evidence emerging of a complex interaction between genetic factors and dysfunction of vital molecular pathways. Glutamate- mediated excitoxicity is an important pathophysiological pathway in ALS, and was identified as an important therapeutic biomarker leading to development of the only pharmacologically based disease-modifying treatment currently available for ALS. More recently, a putative role of voltage-gated persistent Na+ channels in ALS pathogenesis has been suggested and underscored by neuroprotective effects of Na+ channel blocking agents in animal models. In addition, advances in ALS genetics have lead to identification of novel pathophysiological processes that could potentially serve as therapeutic targets in ALS. Genetic therapies, including antisense oligonucleotide approaches have been shown to exert neuroprotective effects in animal models of ALS, and Phase I human trial have been completed demonstrating the feasibility of such a therapeutic approach. The present review summarises the advances in ALS pathogenesis, emphasising the importance of these processes as potential targets for drug development in ALS.
Keywords: Amyotrophic lateral sclerosis, clinical trial, excitotoxicity, glutamate, motor neuron disease, riluzole.
Current Medicinal Chemistry
Title:Biomarkers and Future Targets for Development in Amyotrophic Lateral Sclerosis
Volume: 21 Issue: 31
Author(s): Parvathi Menon, Matthew C. Kiernan and Steve Vucic
Affiliation:
Keywords: Amyotrophic lateral sclerosis, clinical trial, excitotoxicity, glutamate, motor neuron disease, riluzole.
Abstract: Although the pathophysiological mechanisms underlying the development of amyotrophic lateral sclerosis (ALS) remain to be fully elucidated, there have been significant advances in the understanding of ALS pathogenesis, with evidence emerging of a complex interaction between genetic factors and dysfunction of vital molecular pathways. Glutamate- mediated excitoxicity is an important pathophysiological pathway in ALS, and was identified as an important therapeutic biomarker leading to development of the only pharmacologically based disease-modifying treatment currently available for ALS. More recently, a putative role of voltage-gated persistent Na+ channels in ALS pathogenesis has been suggested and underscored by neuroprotective effects of Na+ channel blocking agents in animal models. In addition, advances in ALS genetics have lead to identification of novel pathophysiological processes that could potentially serve as therapeutic targets in ALS. Genetic therapies, including antisense oligonucleotide approaches have been shown to exert neuroprotective effects in animal models of ALS, and Phase I human trial have been completed demonstrating the feasibility of such a therapeutic approach. The present review summarises the advances in ALS pathogenesis, emphasising the importance of these processes as potential targets for drug development in ALS.
Export Options
About this article
Cite this article as:
Menon Parvathi, Kiernan C. Matthew and Vucic Steve, Biomarkers and Future Targets for Development in Amyotrophic Lateral Sclerosis, Current Medicinal Chemistry 2014; 21 (31) . https://dx.doi.org/10.2174/0929867321666140601161148
DOI https://dx.doi.org/10.2174/0929867321666140601161148 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Motor Neuron Disease and Acquired Axonal Neuropathy Association in HIV Infection: Case Report and Update
Current HIV Research Shikimate Kinase (EC 2.7.1.71) from Mycobacterium tuberculosis: Kinetics and Structural Dynamics of a Potential Molecular Target for Drug Development
Current Medicinal Chemistry Complex and Differential Glial Responses in Alzheimer´s Disease and Ageing
Current Alzheimer Research Oxidative/Nitrosative Stress and Immuno-inflammatory Pathways in Depression: Treatment Implications
Current Pharmaceutical Design The NGF Metabolic Pathway in the CNS and its Dysregulation in Down Syndrome and Alzheimer’s Disease
Current Alzheimer Research Cell-Penetrating Peptide Technology to Deliver Chaperones and Associated Factors in Diseases and Basic Research
Current Pharmaceutical Biotechnology Subject Index To Volume 1
Recent Patents on CNS Drug Discovery (Discontinued) Transplantation of Stem Cells as a Potential Therapeutic Strategy in Neurodegenerative Disorders
Current Stem Cell Research & Therapy Role of Long Non-coding RNAs in the Pathogenesis of Alzheimer’s and Parkinson’s Diseases
Current Aging Science Recent Advances in Liver X Receptor Biology and Chemistry
Current Topics in Medicinal Chemistry Neuropsychiatric Disturbances in Alzheimer’s Disease: What Have We Learned from Neuropathological Studies?
Current Alzheimer Research Editorial (Hot Topic: Epidemiology & Risk Factors for Alzheimer’s Disease)
Current Alzheimer Research Commentary((Research Highlights)(Amyotrophic Lateral Sclerosis: Targeting the Body’s Energy Engine))
CNS & Neurological Disorders - Drug Targets Cutting-edge Patents in Alzheimers Disease Drug Discovery: Anticipation of Potential Future Treatments
Recent Patents on CNS Drug Discovery (Discontinued) Mast Cell – Glia Dialogue in Chronic Pain and Neuropathic Pain: Blood-Brain Barrier Implications
CNS & Neurological Disorders - Drug Targets Immunological Approaches to Prevent Neuronal Apoptosis During Neuroinflammation
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Involvement of the Mitochondrial Benzodiazepine Receptor in Traumatic Brain Injury: Therapeutic Implications
CNS & Neurological Disorders - Drug Targets Decreased Regenerative Capacity of Oligodendrocyte Progenitor Cells (NG2-Glia) in the Ageing Brain: A Vicious Cycle of Synaptic Dysfunction, Myelin Loss and Neuronal Disruption?
Current Alzheimer Research Mesenchymal Stem/Stromal Cells: A New "Cells as Drugs" Paradigm. Efficacy and Critical Aspects in Cell Therapy
Current Pharmaceutical Design Amyloid Beta Protein as a Marker or Risk Factor of Alzheimers Disease
Current Alzheimer Research